Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05845450CT.gov Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | — | Recruiting | — | — | — |
NCT05061017CT.gov Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | — | Completed | — | — | — |
NCT04912765CT.gov Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | — | Recruiting | — | — | — |
NCT04599140CT.gov SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | — | Active Not Recruiting | — | — | — |
NCT04044430CT.gov Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT04166383CT.gov VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | — | Terminated | — | — | — |
NCT04362839CT.gov Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03576963CT.gov Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT04017650CT.gov Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04771715CT.gov Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
Show 4 more trialsShow fewer
NCT03377361CT.gov An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | — | Completed | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02423954CT.gov Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | — | Terminated | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Fred Hutchinson Cancer Center | P2 | B · 63 |
| Tipiracil | Mayo Clinic | P2 | BBB |
| Fluorouracilum | City of Hope Medical Center | P4 | BB |
| Oxaliplatin | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Muamycin | City of Hope Medical Center | P3 | BB |
| Capecitabine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Pentoxifylline | Tanta University | P4 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P3 | BB |
+42 more in the Colorectal Carcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Colorectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-colorectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →